CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the following conferences: Leerink Global Healthcare Conference 2025: Fireside chat on Tuesday, March 11, 2025, at 10:50 a.m.
We have just released a list of the 10 Best Small-Cap Stocks to Buy Right Now. In this article, we will examine how Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) compares to other small-cap stocks. The S&P 500 index has hit record highs, delivering returns of more than 20% for the second year in a row.
AGIO reports mixed fourth-quarter 2024 results. Its sole marketed drug, Pyrukynd, drives revenues year over year.
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO ) Q4 2024 Earnings Conference Call February 13, 2025 8:00 AM ET Company Participants Brian Goff - CEO Sarah Gheuens - CMO & Head OF R&D Tsveta Milanova - CCO Cecilia Jones - CFO Chris Taylor - VP, IR & Corporate Communications Conference Call Participants Eric Schmidt - Cantor Fitzgerald Divya Rao - TD Cowen Gregory Renza - RBC Capital Markets Greg Harrison - Scotiabank Chris Raymond - Piper Sandler Alec Stranahan - Bank of America Lydia Erdman - Goldman Sachs Tessa Romero - J.P. Morgan Operator Good morning, and welcome to Agios' fourth quarter 2024 conference call.
– Filed for Regulatory Approval of Mitapivat (PYRUKYND ® ) for the Treatment of Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia in U.S., European Union, Kingdom of Saudi Arabia and United Arab Emirates; PDUFA Goal Date of September 7, 2025 –
If approved, AGIO's Pyrukynd will be the first oral therapy for all thalassemia subtypes. A final decision is expected by Sep. 7.
The fall in AGIO stock comes after reports of an unexpected side effect linked to its sole-marketed drug Pyrukynd in thalassemia patients.
This Industry Outlook article has featured ResMed, Haemonetics, Phibro, and Agios.
The increasing need for medical procedures and efforts to reduce costs are expected to benefit the Zacks Medical-Products industry. Companies like RMD, HAE, PAHC, and AGIO are likely to take advantage of these positive trends.
An ongoing rise in demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. RMD, HAE, PAHC and AGIO are well-poised to gain from the favorable factors.